
Product Data Sheet

Product Name: 16,16-Dimethyl Prostaglandin E2

Cat. No.: GC11133

Chemical Properties

Cas. No. 39746-25-3

Chemical Name (E)-7-((1R,2S,3R)-3-hydroxy-2-((R,E)-3-hydroxy-4,4-dimethyloct-1-en-1-yl)-5-oxocyclopentyl)hept-5-enoic acid

SMILES O[C@H](C1)[C@@H](/C=C/[C@H](C(C)(C)CCCC)O)[C@@H](C/C=C/CCCC(O)=O)C1=OFormula C₂₂H₃₆O₅

M.Wt 380.52

Solubility DMF: >100 mg/ml (from PGE2), DMSO: >100 mg/ml (from PGE2), Ethanol: >100 mg/ml (from PGE2), PBS pH 7.2: >5 mg/ml (from PGE2)

Store
Storage at -
20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available sizes: ship with RT, or blue ice upon request.

Structure **Background**

IC50: N/A

16,16-Dimethyl Prostaglandin E2 (dmPGE2) is the synthetic derivative of prostaglandin E2. Since prostaglandin E has immunosuppressive effects and potentially could lessen the toxic effects of cyclosporine, prostaglandin E usage in the setting of allotransplantation has been suggested both clinically and experimentally.

In vitro: DmPGE2 was reported to cause an increase in runx11/cmyb1 HSCs, while HSCs were inhibited by indomethacin treatment in 90% of embryos. Moreover, dmPGE2 had minimal effects on the vasculature, while indomethacin altered the intersomitic vessels slightly. Imaged by confocal microscopy, red-labelled HSCs and endothelium embryos showed significantly increased HSCs following dmPGE2 exposure [1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

In vivo: In a heterotopic model of rat allograft rejection, dmPGE2 could delay the rejection onset, but all animals developed severe rejection and died subsequently. Treatment of animals with low-dose CsA in combination with dmPGE2 led to a delay in the onset as well as a reduction in the intensity of allograft rejection. In addition, a statistical relationship between procoagulant activity levels and the time of onset of rejection was observed [1].

Clinical trial: N/A

References:

[1] North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, Weber GJ, Bowman TV, Jang IH, Grosser T, Fitzgerald GA, Daley GQ, Orkin SH, Zon LI. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. *Nature*. 2007 Jun 21; 447(7147):1007-11.

[2] Koh IH, Kim PC, Chung SW, Waddell T, Wong PY, Gorczynski R, Levy GA, Cohen Z. The effects of 16, 16 dimethyl prostaglandin E2 therapy alone and in combination with low-dose cyclosporine on rat small intestinal transplantation. *Transplantation*. 1992 Oct; 54(4):592-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA